暂无

一、基金项目（近5年主持或参加的主要项目）

1．国家自然科学基金委员会, 青年科学基金项目（C类）[原青年科学基金项目], 82204191，基于晶体结构的高选择性JAK2-JH2变构抑制剂的设计、合成及其抗骨髓增生性肿瘤（MPNs）活性研究，2023-01-01至2025-12-31，30万元，结题，主持

2．国家自然科学基金委员会，面上项目，82073693，新型选择性TYK2/JAK1小分子抑制剂的设计、合成及其在炎症性肠病（IBD）治疗中的活性研究，2021-01-01至2024-12-31，55万元，结题，参与

3．中国博士后基金会，面上项目，2022M712279，新型选择性ATM小分子抑制剂的设计、合成及其抗肿瘤活性研究，2022-12至2024-12，8万元，结题，主持

4．四川省科技厅，青年科学基金项目，2022NSFSC1341，新型选择性GLS1小分子抑制剂的设计、合成及其在肿瘤治疗中的活性研究，2022-01至2023-12，10万元，结题，主持

二、论文（近5年的代表性论著）

(1) Ma Y*, Pan S*, Yang T*, Liao B, Yang M, Fu Y, Jin X, Yang D, Chu C, Wang K#, and Zhao M#. Multi-omics analyses reveal a rhamnogalacturonan I (RG-I) from Polygonum aviculare ameliorates nephrolithiasis through regulation of the gut-kidney axis. Carbohydr. Polym. 2026, 378:124918. (共同第一作者；IF=12.5)

(2) Yang T*, Guo T*, Yuan Y*, Tang M, Cui X, Zhao M#, Qin M^#, and Yang Z^#. Rational design of novel pyrazolo[4,3-c]quinoline derivatives as potent, selective, and orally bioavailable ATM inhibitors with promising in vivo efficacy. J. Med. Chem. 2026, 69(4): 4677-4696. (共同第一作者；IF=6.8)

(3) Tian Y*, Liu Y*, Liu J*, Luo J, Zhang J, Zhang X, He H, Xiao Y, Zhang J#, and Yang T^#. Identification of a novel benzyloxy-terminated scaffold as a potent and selective TYK2 inhibitor for anti-inflammatory therapy. Eur. J. Med. Chem. 2026; 301:118211. (共同通讯作者；IF=5.9)

(4) Lin Y*, Tao Y*, Yi W*, Ming T, Ya T, Wan Z, Yun Z, Li C, and Zhuang Y^#. Design and synthesis of novel deazapurine DNMT 1 inhibitors with in vivo efficacy in DLBCL. J. Med. Chem. 2025 68 (5), 5333-5357. (共同第一作者；IF=6.8)

(5) Guo T*, Qin S*, Tian Y*, Tang M, Yuan Y, Sun R, Chen L, Cen X, and Yang T#. Discovery of 1H-pyrrolo[2,3-b]pyridine derivatives as highly selective, and orally available ATM inhibitors with potent in vivo antitumor activity. J. Med. Chem. 2025; 68(13):13907-13934. (唯一通讯作者；IF=6.8)

(6) Qin S*, Wu R*, Tian Y*, Tang M, Yan W, Cen X, Chen L^#, and Yang T^#. Discovery of highly selective and potent macrocyclic JAK2 inhibitors for the treatment of MPNs. J. Med. Chem. 2025;6 8(16):17933-17959. (共同通讯作者；IF=6.8）

(7) Kong L*, Xue Y*, Tao Y*, De D, Yong C, Ming T, Chu Z, Yu Z, Shun Z, Dan L, Ming S, Yong G, Yan Z, Min Z, Zhuang Y, and Chen L^#. Discovery, optimization, and evaluation of potent and selective DNA-PK inhibitors in combination with chemotherapy or radiotherapy for the treatment of malignancies J. Med. Chem. 2024, 67, 1, 245–271. (共同第一作者；IF=6.8)

(8) Peng W*, Yong Y*, Tao Y*, Yu Z, Ming T, Zi M, Wei B, Song Q, Yong C, Tao G, Zhong G, Jian Y Ming X^#, and Li C^#. Design, synthesis, and biological evaluation of 5-amino-4-fluoro-1H-benzo[d]imidazole-6-carboxamide derivatives as novel and potential MEK/RAF complex inhibitors based on the “Clamp” strategy. J. Med. Chem. 2024 67 (17), 15246-15267. (共同第一作者；IF=6.8)

(9) Tian Y*, Qin S*, Zhang F, Luo J, He X, Sun Y, and Yang T^#. Discovery of N‑(4-(aminomethyl)phenyl)-5-methylpyrimidin-2-amine derivatives as potent and selective JAK2 inhibitors. ACS Med. Chem. Lett. 2023, 14, 1113−1121. (唯一通讯作者, IF=4.2)

(10) Yang T*, Yang Y*, Chen Y*, Tang M, Shi M, Tian Y, Yuan X, Yang Z#, and Chen L#. Rational design and appraisal of selective Cdc2-like kinase 1 (CLK1) inhibitors as novel autophagy inducers for the treatment of acute liver injury (ALI). E. J. Med. Chem. 2023, 250, 115168. (共同第一作者；IF=5.9)

(11) Yang T*, Tian Y*, Yang Y*, Tang M, Shi M, Chen Y, Yang Z#, and Chen J#. Design, synthesis, and pharmacological evaluation of 2-(1-(1,3,4-thiadiazol-2-yl)piperidin-4-yl)ethan-1-ol analogs as novel glutaminase 1 inhibitors. E. J. Med. Chem. 2023, 243, 114686. (共同第一作者；IF=5.9)

(12) Yang T*, Cui X*, Tang M*, Qi W, Zhu Z, Shi M, Yang L, Pei H, Zhang W, Xie L, Xu Y, Yang Z^#, and Chen L^#. Identification of a novel 2,8-diazaspiro[4.5]decan-1-one derivative as a potent and selective dual TYK2/JAK1 inhibitor for the treatment of inflammatory bowel disease. J Med Chem. 2022; 65(4):3151-3172. (共同第一作者；IF=6.8)

(13) Hu M*, Yang T*, Yang L*, Niu L*, Zhu J, Zhao A, Shi M, Yuan X, Tang M, Yang J, Pei H, Yang Z, Chen Q, Ye H, Niu T^#, and Chen J^#. Preclinical studies of Flonoltinib Maleate, a novel JAK2/FLT3 inhibitor, in treatment of JAK2V617F-induced myeloproliferative neoplasms. Blood Cancer J. 2022, 12, 37. (共同第一作者, IF=11.6)

三、专利

1．ZL202510107925.4，一种对JAK2具有选择抑制作用的化合物、其用途及其药物，杨涛，2025-04-04，发明，中国

2．202510554763.9，一类含二取代 7-氮杂吲哚结构的化合物及应用，杨涛、岑小波、杨壮，2025-04-29，发明，中国